Company intelligence / Profile preview

ABAStroke

Ownership: Private
Development stage: Commercial

Overview

ABAStroke has developed an AI-powered mobile app for home-based cognitive rehabilitation after stroke. In a clinical study with 74 participants, the app led to an average improvement of +3.69 points on the Montreal Cognitive Assessment (MoCA) test versus +2.00 points in controls—an additional improvement of about 84% over standard care alone. The company continues to develop its product toward regulatory certification and reimbursement pathways such as DiGA in Germany and CE marking across Europe.

Therapeutic areas: Neurology
Modalities: Non-pharmacological therapy (digital cognitive rehabilitation)Device (Software as a Medical Device)Artificial intelligence-based therapy
Industry: Digital Health Medical Devices

Partnerships

Revolve Healthcare (software development & regulatory partner)

Beyond the preview

Go deeper on ABAStroke.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABAStroke.

Explore the full profile